Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 10, 2026, 2:01 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1945–1968 of 79,351 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: 2 Clear all

Conditions: Healthy
Interventions: ZD4054; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 65 Years · Male only
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Prostate Cancer
Interventions: Capivasertib, Enzalutamide, Abiraterone; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 130 Years · Male only
Enrollment: 27 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 5
States / cities: Indianapolis, Indiana • Omaha, Nebraska • White Plains, New York + 2 more

Conditions: Diabetes Mellitus, Type 2
Interventions: LY3502970, Placebo; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 68 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 4
States / cities: Hialeah, Florida • Marlton, New Jersey • Dayton, Ohio + 1 more

Conditions: Mental Health
Interventions: Radical Healing and Internalized Stigma (RHIS) Training; Other
Lead sponsor: University of Wisconsin, Madison; Other
Eligibility: 18 Years and older
Enrollment: 51 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Helicobacter Pylori Infection
Interventions: Not listed
Lead sponsor: University of Louisville; Other
Eligibility: 18 Years to 90 Years
Enrollment: 220 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2012
U.S. locations: 2
States / cities: Louisville, Kentucky • Somerset, Kentucky

Conditions: Immune Response
Interventions: cardiovascular exercise training, flexibility/balance control; Behavioral
Lead sponsor: National Institute on Aging (NIA); NIH
Eligibility: 62 Years to 82 Years
Enrollment: 150 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2002 – 2006
U.S. locations: 1
States / cities: Urbana, Illinois

Conditions: Prostate Cancer
Interventions: LY2452473, Placebo; Drug
Lead sponsor: Dana-Farber Cancer Institute; Other
Eligibility: 19 Years and older · Male only
Enrollment: 114 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2020
U.S. locations: 4
States / cities: Gainesville, Florida • Baltimore, Maryland • Boston, Massachusetts

Conditions: Asthma in Children
Interventions: Asthma CHAMPS full program, Asthma CHAMPS Wait List Control; Behavioral
Lead sponsor: Johns Hopkins University; Other
Eligibility: Not listed
Enrollment: 1,000 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2027
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Influenza
Interventions: Influenza A Vaccine: ACAM FLU-A, Saline placebo; Biological
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years to 40 Years
Enrollment: 87 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2009
U.S. locations: 3
States / cities: Miami, Florida • Lenexa, Kansas • Tacoma, Washington

Conditions: Staphylococcus Aureus Bacteremia
Interventions: Early Dual IV Antibiotic Therapy - MRSA, Early Dual IV Antibiotic Therapy - MSSA, Single Agent IV Antibiotic Therapy - MRSA, Single Agent IV Antibiotic Therapy - MSSA; Drug
Lead sponsor: West Virginia University; Other
Eligibility: 18 Years and older
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Morgantown, West Virginia

Conditions: Sickle Cell Disease
Interventions: Single Session Problem-Solving Intervention; Behavioral
Lead sponsor: University of Texas Southwestern Medical Center; Other
Eligibility: 7 Years and older
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2022
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Leukemia
Interventions: nelarabine; Drug
Lead sponsor: SWOG Cancer Research Network; Network
Eligibility: 16 Years and older
Enrollment: 35 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2000 – 2004
U.S. locations: 107
States / cities: Mobile, Alabama • Phoenix, Arizona • Tucson, Arizona + 69 more

Conditions: Post Operative Pain
Interventions: SABER-Bupivacaine (Part 1), SABER-Bupivacaine (Part 2), Saline Placebo, Bupivacaine HCl; Drug
Lead sponsor: Durect; Industry
Eligibility: 18 Years and older
Enrollment: 399 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 21
States / cities: Florence, Alabama • Sheffield, Alabama • Arcadia, California + 13 more

Conditions: Asthma
Interventions: budesonide, placebo; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 6 Years to 11 Years
Enrollment: 304 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2013
U.S. locations: 57
States / cities: Scottsdale, Arizona • Fresno, California • Granada Hills, California + 54 more

Conditions: Diabetic Macular Edema, DME, Diabetic Macular Edema (DME)
Interventions: EYP-1901, Aflibercept (2.0 mg); Drug
Lead sponsor: EyePoint Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 240 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 51
States / cities: Gilbert, Arizona • Phoenix, Arizona • Scottsdale, Arizona + 44 more

Conditions: Autism Spectrum Disorder, Autism
Interventions: MINDful TIME; Behavioral
Lead sponsor: Southwest Autism Research & Resource Center; Other
Eligibility: 13 Years to 18 Years
Enrollment: 28 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 1
States / cities: Phoenix, Arizona

Conditions: Plasmodium Vivax Malaria
Interventions: Malaria Challenge; Biological
Lead sponsor: U.S. Army Medical Research and Development Command; Federal
Eligibility: 18 Years to 55 Years
Enrollment: 12 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2011
U.S. locations: 1
States / cities: Silver Spring, Maryland

Conditions: Sepsis
Interventions: Muscle stimulation with Niveus medical stimulator, measurement of maximal isometric twitch strength, Muscle Biopsy, Muscle Biopsy Medication: Lidocaine, Muscle Biopsy Medication: Versed, Muscle Biopsy Medication: Fentanyl, Blood and Urine Sampling, ineffective muscle stimulation; Device · Procedure · Drug + 1 more
Lead sponsor: University of Florida; Other
Eligibility: 18 Years and older
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 1
States / cities: Gainesville, Florida

Conditions: HER2-expressing Cancers
Interventions: ZW25 (Zanidatamab), Paclitaxel, Capecitabine, Vinorelbine, Tucatinib; Drug
Lead sponsor: Jazz Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 279 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2024
U.S. locations: 9
States / cities: Birmingham, Alabama • Los Angeles, California • Newport Beach, California + 6 more

Conditions: Perianal Abscess, Anal Fistula
Interventions: Amoxicillin + Clavulanate, Ciprofloxacin + Metronidazole; Drug
Lead sponsor: University of Illinois Chicago; Other
Eligibility: 18 Years and older
Enrollment: 236 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Metastatic or Locally Advanced Unresectable Pancreatic Adenocarcinoma
Interventions: TH-302, Gemcitabine, Placebo (5 percent dextrose - D5W); Drug
Lead sponsor: ImmunoGenesis; Industry
Eligibility: 18 Years and older
Enrollment: 693 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2016
U.S. locations: 1
States / cities: Rockland, Massachusetts

Conditions: Breast - Female, Male Breast Cancer
Interventions: Pembrolizumab, Paclitaxel; Drug
Lead sponsor: Wake Forest University Health Sciences; Other
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2022
U.S. locations: 1
States / cities: Charlotte, North Carolina

Conditions: Cancer
Interventions: CNTO888+DOXIL®/ Caelyx® doxorubicin HCl liposome injection, CNTO888 + gemcitabine, CNTO888 + Paclitaxel and carboplatin, CNTO888 + docetaxel; Drug
Lead sponsor: Centocor, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 53 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 2
States / cities: Detroit, Michigan • Tacoma, Washington

Conditions: Pancreatic Cancer
Interventions: Capecitabine, PHY906; Drug
Lead sponsor: Yale University; Other
Eligibility: 18 Years and older
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2009
U.S. locations: 1
States / cities: New Haven, Connecticut

Search by objective public record fields.

Relative Bioavailability Study in Healthy Male Subjects for ZD4054 (Zibotentan) Immediate Release Tablets.

A Multi-centre Study to Assess the Safety, Tolerability, and Pharmacokinetics of Capivasertib (AZD5363) in Combination With Novel Agents in Patients With Metastatic Prostate Cancer

A Study of LY3502970 in Participants With Type 2 Diabetes

Psychotherapy Interventions to Support Transgender, Two-Spirit, and Nonbinary People of Color

Oral H. Pylori Prevalence in Intellectually & Developmentally Disabled Adults

The Immune Function Intervention Trial

A Selective Androgen Receptor Modulator for Symptom Management in Prostate Cancer

Implementation of Asthma Community Home and School Management Program (Asthma CHAMPS)

Safety Study of Recombinant M2e Influenza-A Vaccine in Healthy Adults

Does Staphylococcus Aureus Bacteremia Early Dual Therapy Improve Outcomes?

Utilizing A Single Session Problem-Solving Intervention With Caregivers of Pediatric Patients Receiving Chronic Transfusion to Treat Sickle Cell Disease

S0010 506U78 in Treating Patients With Recurrent or Refractory Acute Lymphocytic Leukemia

Trial of Extended Release Bupivacaine for Pain Relief After Surgery

A 6-week Study in Asthmatic Children Aged 6 to <12 Yrs Comparing Budesonide pMDI 160ug Twice Daily With Placebo

CAPRI: A Phase 3 Randomized, Double-Masked Study Comparing the Efficacy of EYP-1901 Against Aflibercept in DME

In-Person Mindfulness-based Intervention for Adolescents With Autism Spectrum Disorder and Their Caregivers

Clinical Trial for the Development of a Safe Malaria Challenge Model That Can be Reproduced in Humans

Project 4B: Lower Extremity Strength Training in ICU Patients

Trial of ZW25 (Zanidatamab) in Patients With Advanced HER2-expressing Cancers

Antibiotics After Incision and Drainage to Prevent Fistula Formation After First Episode of Perianal Abscess

Clinical Trial Testing TH-302 in Combination With Gemcitabine in Previously Untreated Subjects With Metastatic or Locally Advanced Unresectable Pancreatic Adenocarcinoma

Pilot Study of Paclitaxel Plus Pembrolizumab in Metastatic HER2-Negative Breast Cancer

A Study of the Safety and Efficacy of CNTO 888 in Combination With SoC (Standard of Care) Chemotherapy in Patients With Solid Tumors

A Phase I/II, Multi-Center, Open-Label, Dose-Escalation, Safety and Efficacy Study of PHY906 Plus Capecitabine in Patients With Advanced Pancreatic Carcinoma